Cryptococcal disease: implications of recent clinical trials on treatment and management.
Aberg
J A
JA
University of California, San Francisco, USA.
Powderly
W G
WG
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003453:Cryptococcosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D003454:Cryptococcus / Q000472:pathogenicity; D003881:Dermatomycoses / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D016919:Meningitis, Cryptococcal / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology
D000935:Antifungal Agents